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ABSTRACT
Work-related asthma (WRA) is one of the most common
occupational respiratory conditions, and includes
asthma specifically caused by occupational exposures
(OA) and asthma that is worsened by conditions at
work (WEA). WRA should be considered in all adults
with asthma, but especially those with new-onset or dif-
ficult to control asthma. Improvement in asthma symp-
toms when away from work is suggestive of WRA.
Clinical history alone is insufficient to diagnose WRA;
therefore, objective investigations are required to con-
firm the presence of asthma and the association of
asthma with work activities. Management of WRA
requires pharmacotherapy similar to that of non-WRA,
however, also needs to take into account control of the
causative workplace exposure. Ongoing exposure will
likely lead to decline in lung function and worsening
asthma control. WRA is a preventable condition but this
does rely on increased awareness of WRA and thorough
identification and control of all potential occupational
respiratory hazards.
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Asthma affects approximately 2.7 million Australians,
and remains a significant cause of death, with more
than 400 people dying of asthma in Australia in 2017.
More than one-third of people with asthma report
that this significantly affects their daily living, and
the economic and social costs of asthma remain high
despite improvements in treatment. Work-related
causes of asthma are often forgotten about by
patients and healthcare professionals, yet remain an
important preventable cause of morbidity and
disablement.
Work-related asthma (WRA) is a general term which
includes both asthma caused by an inciting exposure
in the workplace (occupational asthma, OA) and
asthma that is worsened by workplace conditions
(work-exacerbated asthma, WEA) (Fig. 1).1 WRA is a
common occupational lung disease in developed, low-
and middle-income countries and is generally prevent-
able.2 It is estimated that 25% of adults with asthma
have WRA.1,3 Although WRA is likely to be encountered
frequently in clinical practice, it remains under-
recognized and under-reported.4 Failure to identify and
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manage WRA may lead to worsening asthma control.
Conversely, inaccurate diagnosis may lead to unneces-
sary absence from work and potential economic
hardship.5
The purpose of the position paper is to increase
awareness of the association between work and
asthma, and provide a structure for diagnosis and man-
agement. The paper is intended to provide general
advice and does not represent guidelines. The target
audience is all healthcare professionals who manage
patients with asthma. The clinical relevance of the
paper will be reviewed 5 years after the date of
publication.
In accordance with the Thoracic Society of Australia
and New Zealand (TSANZ) policy, a call for expressions
of interest was sent to all members of the Society. Fol-
lowing review of provided curriculum vitae, the posi-
tion paper writing group was established with
10 respiratory physicians and 1 occupational physician.
Based on their areas of expertise, members were
assigned specific sections to undertake a comprehen-
sive literature review and develop draft recommenda-
tions. Inclusion of articles was determined by the
assigning author and they were not systematically
reviewed. All drafted sections were reviewed by the
entire group for the opportunity to provide further con-
tributions. Three authors (R.H., J.R. and J.B.) then com-
piled and edited the manuscript. All authors reviewed
and approved the final manuscript.
DEFINITIONS
OA is new-onset asthma, or the recurrence of previ-
ously quiescent asthma, induced by an occupational
exposure. The timely diagnosis of OA is important
as ongoing exposure to the causative agent
may result in rapid and often irreversible decline in
lung function.6,7 OA can be characterized as
sensitiser-induced or irritant-induced occupational
asthma.
Sensitiser-induced OA is the most common form of
OA (approximately 90%) and may be caused by high-
or low-molecular weight (HMW and LMW) agents.1
Sensitiser-induced OA is characterized by develop-
ment of asthma after a latency period ranging
between days and years after initial occupational
exposure. HMW agents (>10 kDa) act as antigens and
induce production of antigen-specific IgE.8 Although
some LMW agents also induce specific IgE by acting
as haptens, most LMW chemicals induce asthma via
cellular immune-mediated pathways. Sensitisation to
more than one occupational agent may occur, and
more than one mechanism can be involved in any
individual. The phenotypes of HMW and LMW OA
appear to differ. An international multicentre study
noted that HMW OA was more associated with work-
related rhinitis, early asthmatic reactions and airflow
limitation, and LMW OA more with work-related
chest tightness, late reactions and severe
exacerbations.9
Over 300 workplace agents have been described to
cause OA (Table 1).10 Australian prevalence data from
2014 showed that occupational exposure to one or
more agent is common (47% men, 40% women).11
Among men, common exposures include bioaerosols
(29%), metals (27%), arthropods/mites (25%) and latex
(22%), and among women: latex (25%), industrial
cleaning and sterilizing agents (20%), bioaerosols (18%)
and arthropods/mites (16%).
The primary risk factor for the development of
sensitiser-induced OA is the level or dose of workplace
exposure to the inciting agent, but the duration of
exposure is also important.14 A history of atopy also
confers a higher risk of developing sensitiser-induced
OA when exposed to HMW antigens. A history of
smoking is a risk factor for the development of OA for
most antigens, but this has not been demonstrated
for all.
Where uncertainty exists regarding exposure to
potential agents, there are useful web-based lists of
agents with search tools which can help in deciding
whether an agent is a likely cause of OA (e.g. www.
occupationalasthma.com and www.aoecdata.org).
In 1985, Brooks described reactive airway dysfunction
syndrome (RADS) as sudden-onset asthma occurring
within a few hours of a single high-level exposure to an
irritant substance.15 Subsequently, the term irritant-
induced (occupational) asthma (IIA) has been utilized
more widely. IIA includes the RADS clinical phenotype,
but also development of asthma in workers with multi-
ple irritant exposures and asthma with a delayed onset
after chronic exposure to moderate levels of
irritants1,4,15–17 (Table 2). The association between IIA
and frequent low-level exposures to respiratory irritants
is not entirely clear, but has been described in case
reports and small case series involving cleaners
(domestic and industrial), nurses, textile workers, poul-
try workers and aluminium pot room workers.4,20
There has been increasing recognition of the associa-
tion between cleaning agents and disinfectants and
asthma, in particular formaldehyde, glutaraldehyde,
hypochlorite bleach, hydrogen peroxide and enzymatic
cleaners.21 There is evidence that irritant mechanism is
more common in association with these agents; how-
ever, an immunological mechanism has been noted in
case reports.22
Although the definitive pathogenic mechanism
remains unclear, IIA is likely due to bronchial epithelial
cell damage resulting in pro-inflammatory responses,
neurogenic inflammation due to exposed nerve end-
ings, increased lung permeability and remodelling of
the airway epithelium.18
Figure 1 Relationship of asthma to the workplace (Reproduced
from Tarlo et al.,1 with permission).
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WEA describes the exacerbation of pre-existing or
coincident (new-onset, non-occupational) asthma
because of workplace conditions.16 WEA may present
with increased symptom frequency, medication use or
acute exacerbations. Conditions at workplaces that can
exacerbate asthma are common and varied (Table 2).16
WEA is common, with a median prevalence of 21.5%
among adults with asthma.16
EPIDEMIOLOGY
To date, epidemiological estimates of WRA have been
wide-ranging. Surveillance-based systems suggest that
the incidence of OA is approximately 4–17/100 000
workers per year,23,24 although data from a prospective
multi-national survey, which included Australia, sug-
gest that the incidence may be as high as
Table 1 Summary of workplace agents causing sensitiser-induced occupational asthma4,10–13
Agent At-risk occupations
High-molecular weight agents (>10 kDa3)
Plant allergens Grains, cereals (e.g. rye, soya, malt and
wheat flour)
Farmers, bakers, millers, combine harvester
drivers
Dust (tea, tobacco, coffee beans) Packers, cafe workers
Flowers, pollen Florists, gardeners
Vegetable gums Pharmaceutical industry, carpet factory workers
Cotton Textile industry workers
Hay Farmers
Psyllium Healthcare workers
Latex Healthcare workers, toy and medical equipment
manufacturers
Animal allergens Dander, excreta Laboratory workers, veterinary workers, farmers,
breeders, animal handlers, groomers
Insects Laboratory workers, entomologists
Bird products, egg protein Process workers, breeders, poultry and hatchery
workers
Crustaceans, seafood Process workers, cooks, fishermen
Enzymes Protease, amylase, lipase, cellulase Detergent manufacturers, warehouse workers,
bakers, cleaners, hospital staff
Fungi Moulds, yeasts Food processors, bakers, farmers
Low-molecular weight agents (<10 kDa3)
Chemicals Isocyanates Spray painters, adhesive workers, polyurethane
foam manufacturers, insulation workers,
automotive industry
Formaldehyde Embalmers, healthcare workers, cosmetic industry
Glutaraldehyde Laboratory workers, tanners, plastic industry
workers, endoscopists
Dyes and bleaches Fabric and fur dyers, hairdressers
Alkaline persulphates Hair dressers, plastic and synthetic rubber
manufacturers
Complex amines Agrichemical and pharmaceutical manufacturers
Fungicides Gardeners
Glues and resins (epoxy, acrylates, acid
anhydrides)
Flooring installers, tilers, plastic manufacturers,




Platinum salts, nickel, cobalt, chromium,
iron, tin, zinc oxide, titanium, stainless
steel, tungsten
Metal platers and galvanizers, electronic industry
workers, photographers, dentists, chemists
Aluminium pot room
emission
Aluminium fluoride, chlorine, sulphur
dioxide, hydrofluoric acid
Aluminium smelter workers
Pharmaceuticals Penicillins, tetracycline, cephalosporins,
opiates, colistin
Chemists, healthcare professionals
Solder flux Colophony Metallurgists, jewellery makers, artists, electronics
workers, welders
Wood dusts Western red cedar (plicatic acid), oak,
redwood, chicory, exotic woods
Carpenters, saw mill workers, arborists, sanders
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25–30/100 000 people per year.25 The no longer opera-
tional voluntary reporting scheme SABRE (Surveillance
of Australian workplace Respiratory Based Events)
recorded an incidence of OA of 0.5/100 000 workers
per year in NSW and 3/100 000 in Victoria.26 These
rates are far lower than similar countries overseas,
likely to be due to under-reporting to this scheme.26
Finland has one of the most comprehensive data sets
regarding work-related disease due to compulsory phy-
sician reporting of all known or suspected occupational
diseases.23 The Finnish Registry of Occupational Dis-
ease (FROD) reported a mean OA annual incidence
rate of 17.4 cases/100 000 employed workers.23 Cases
caused by animal allergens, or flours, grains and fod-
ders accounted for 60% of the total.
The population burden of asthma attributable to
occupational exposures has been estimated to be
between 15% and potentially as high as 20%,27
although studies using strict definitions of OA suggest
attributable fraction closer to 4.7%.24 In Australia, esti-
mates of new cases of asthma caused by work range
from approximately 1000 to 3000 per year.28 There are
limited data on the contribution of irritants to OA inci-
dence. Survey data from New South Wales estimated a
population attributable risk to new-onset asthma due
to work of 9.5% overall and 0.2% for irritant expo-
sures.29 However, early data from Canada noted that
IIA was relatively common among a sample of workers
diagnosed with OA at a specialist occupational lung
disease clinic (10/59).17
WEA has been noted to be a common condition.30 An
American Thoracic Society (ATS) consensus statement
reviewed 12 general population or primary healthcare
studies noting an average prevalence of 21.5% (range:
13–58%) of WEA among working asthmatic patients.16
Other studies using more objective measures of asthma
control (interviews, serial peak expiratory flow (PEF)
measures and medication usage) identified WEA preva-
lence of 13–22% among all those with asthma.31
CLINICAL FEATURES
A relationship between asthma and exposures in the
work setting should be considered in all people of
working age with asthma, particularly if asthma
develops during adult life or has been difficult to
control.
A detailed history of clinical symptoms is required
to determine if symptoms are consistent with asthma
or an alternative diagnosis (Table 3). An OA screening
questionnaire has been developed (OASQ-11) and has
moderate discrimination for OA when used in a clini-
cal setting.36 Typical asthma symptoms include epi-
sodic breathlessness, wheeze, cough or chest
tightness.37 The presence of work-related dysphonia
and cough has been noted to be more common with
work-associated irritable larynx syndrome than
asthma, especially when associated with sensory irri-
tants including odours, perfumes, exhaust fumes and
cleaning products.35 Symptoms of occupational aller-
gic rhinitis (nasal itch, rhinorrhoea and congestion)
often precede symptoms of asthma especially related
to HMW agents.38 Asthma present before occupational
exposure, but associated with worsening at the start of
a new occupational exposure, suggests the presence
of WEA.
Irritant-induced OA symptoms commence at the
time of inducing workplace exposure. However,
sensitiser-induced OA is characterized by a period of
latency between first exposure to the occupational
agent and development of asthma symptoms. This
period may range from days to years. Subsequently,
symptoms typically improve during times away from
work, such as weekends and holidays, and worsen at
work. This temporal association of symptoms lessens
when asthma becomes more prolonged or severe.
Table 2 Common workplace exposures associated with
work-exacerbated asthma and irritant-induced
asthma16,18,19














Table 3 Differential diagnosis of work-associated
respiratory symptoms and diagnostic evaluation
Condition Diagnostic evaluation
WRA Refer to Table 4




















Rhinosinusitis Clinical history, CT sinuses,
specific IgE antibodies
Eosinophilic bronchitis FeNO, induce sputum cytology




Psychogenic factors Clinical history
COPD, chronic obstructive pulmonary disease; CT, computed
tomography; FeNO, fractional exhaled nitric oxide; WILS, Work-
associated Irritable Larynx Syndrome; WRA, work-related
asthma.
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A detailed work exposure history should be obtained
to identify likely exposure(s) known to cause WRA
(Tables 1,2). The patient should be asked to provide a
detailed description of his/her work schedule, tasks and
exposures, and of possible exposures related to other
activities in the environment. Details of control strategies
including respiratory protection and ventilation should
be obtained. The patient should request that their
employer provide safety data sheets (SDS) relevant for
their work environment. SDS are documents that provide
critical information about hazardous chemicals. How-
ever, these sheets may be incomplete and not identify
the potential of the agent to cause asthma.
INVESTIGATIONS
Clinical history alone is insufficient to accurately diag-
nose WRA.39 Objective investigations are required to:
1. Confirm the presence of asthma (symptoms, vari-
able airflow obstruction and/or non-specific bron-
chial hyperresponsiveness (NSBH)).
2. Evaluate the association between asthma and the
workplace.
3. Demonstrate sensitisation to, or identify in other
ways, the specific causal agent (wherever possible).
Investigations should be commenced as soon as
WRA is suspected and should be performed when the
worker is still in the role suspected to be associated
with asthma. Relocation during the process of investi-
gating WRA is only necessary if asthma is severe.
Given the individual limitations of investigations, an
approach which includes clinical history and a combina-
tion of testing will increase diagnostic accuracy1,4 (Table 4).
The following are suggested:
1. Confirm the presence of asthma
Spirometry with bronchodilator reversibility assess-
ment should be performed in every worker with
suspected WRA in accordance with best practice guide-
lines to identify variable airflow limitation.37,40 The
presence of expiratory airflow limitation (forced expira-
tory volume 1 s/forced vital capacity (FEV1/FVC)
< lower limit of normal for age) and FEV1 increase
≥200 mL and ≥12% from baseline in response to a
β2-agonist is consistent with the diagnosis of asthma in
this context.37 However, normal spirometry at the time
of initial assessment does not rule out the diagnosis of
asthma. The quality of spirometry is important and
may give clues to the possibility of other diagnoses.
If spirometry does not identify variable airflow limi-
tation, then bronchial provocation testing should be
considered to identify the presence of NSBH.
Bronchial provocation testing in the setting of OA
has a high sensitivity (84%) and a high negative predic-
tive value (75%),41 such that a negative test or a lack of
NSBH in a symptomatic individual, especially if per-
formed within 24 h of work exposure, can generally be
used to rule out active asthma.1,42 Assessment for
NSBH should be carried out when the patient is still
exposed to the suspected offending agent, as airway
hyperreactivity can return to normal rapidly once expo-
sure ceases.42 A negative bronchial provocation test is
helpful in excluding active asthma, but due to low
specificity and low positive predictive value, a single
positive test should be interpreted in combination with
other investigations and clinical aspects.43
Bronchial provocation testing can be done using
either direct agents (methacholine or histamine) or
indirect agents (mannitol). The latter is now commonly
used in Australian laboratories and has been shown in
a small study to be positive in patients with more active
disease,44 but there are more data on methacholine.
2. Evaluation of association between asthma and work
exposure
Serial NSBH
Comparison of bronchial hyperreactivity at work and
after a 10- to 14-day period away from the work expo-
sure has shown moderate sensitivity and specificity for
diagnosing WRA. A 2- to 3-fold change in the dose of
methacholine or histamine needed for a positive test is
considered significant.1 There is only a slightly greater
sensitivity with reduced specificity compared to using
PEF measurements alone.
Serial PEF
The use of recording PEF during periods at and off
work is helpful and can be evaluated visually by experi-
enced respiratory and occupational physicians,
although this method has been shown to have moder-
ate between- and within-expert agreement.45 If there
are expert disagreements, computer evaluations using
quantitative analysis of changes in mean PEF values
can be used (OASYS-2; OASYS Research Group, Mid-
land Thoracic Society, Birmingham, UK, http://www.
occupationalasthma.com/occupational_asthma_
pageview.aspx?id=4443).43 Computer-based analysis
has an equivalent sensitivity to visual inspection tech-
nique but greater specificity (91% vs 69%) and would
be useful in confirming OA.43
PEF measurements should be recorded four times
per day (on awakening, noon, at the end of working
day and before bedtime) for a total of 4 weeks, includ-
ing 2 weeks away from work.1 Cross-shift PEF or FEV1
seems to be less reliable than serial PEF testing. The
cross-shift method has a high specificity (91%) but a
low sensitivity (50–60%).46
Specific inhalation challenge
Specific inhalation challenge (SIC) involves exposing
workers who are suspected of having sensitiser-induced
OA to the presumed causative agent in a safe and con-
trolled manner within an enclosed challenge room.1,47
However, SIC testing requires a high level of expertise
and is only performed in a few centres around the world.
International guidelines recommend a 3- to 4-day proto-
col of testing and admission to hospital for the duration
of the challenge test due to the risk of late phase exces-
sive reactions.47 At this time, SIC testing is not routinely
available in Australia or New Zealand.
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3. Demonstrate sensitisation to, or identify, the specific
causal agent (where possible)
Only a few of the 300 known asthma-causing agents
are commercially available for testing. Skin prick tests
(SPT) and assessment of serum allergen-specific IgE
(sIgE) antibodies are useful to demonstrate IgE-medi-
ated sensitisation to many HMW and some LMW
agents. Other than latex, cat and bee venom extracts,
there is a worldwide relative lack of standardization
and validation for other occupational agents. SPT with
LMW agents should be performed with caution as




Required criteria (need all for a
definite diagnosis) Supportive criteria Required criteria
New-onset asthma or recurrence
of previously quiescent
asthma1,4
Diagnosis of asthma made on the
basis of BOTH:
• Characteristic symptoms4,32
• Lung function testing showing
either variable airflow limitation
or NSBH4,32
Onset of asthma symptoms after a
period of latency following initial
exposure to a sensitiser in the
work environment4,32
Asthma symptoms occurring in
association with work and
exhibiting remission or
improvement during periods off
work1,4,32
• Symptoms may occur at the
beginning or end of the shift or
in the evening after working
hours1,4
Objective association between
asthma and the workplace.4,32
The following criteria should be
sought in all patients and at least
ONE should be present for a
diagnosis1,4,32
• The occupational exposure
preceding symptoms is a known
asthma sensitiser. Specific
immunological testing should be
considered where available
• In patients still working (or on
return to work), serial testing to
show at least ONE of:




3. Work-related worsening of
airflow obstruction on
spirometry














one or more high-level
exposures4,32
Symptoms can begin ≤24 h
and up to several days
after exposure4
Occupational exposure to












obstruction or NSBH on
lung function testing or
medication usage prior to
occupational
exposure4,16,32
Presence of conditions at
work that can exacerbate
asthma (Table 2)16,32
Demonstration of worsening













OA is unlikely.16 An
exacerbation of OA due to
the initial causative agent
is considered an
exacerbation of OA16
FeNO, fractional exhaled nitric oxide; NSBH, non-specific bronchial hyperresponsiveness; OA, occupational asthma; PEF, peak expi-
ratory flow.
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allergenic extracts are not standardised and most of
these agents are potentially irritant to the skin and may
produce false-positive results with lower specificity.
Combination testing
Combining the presence of NSBH with a positive
SPT or sIgE test markedly increased the specificity of
NSBH assessment alone, while sensitivity was not con-
sistently improved.43,48 Assessment of indices of eosin-
ophilic airway inflammation (fractional exhaled nitric
oxide (FeNO) ≥ 25 ppb or a sputum eosinophil
count ≥ 1%) has also recently been demonstrated to
increase the sensitivity of evaluation when performed
in combination with NSBH assessment.33
DIAGNOSIS
WRA should be suspected in all adults with asthma, but
in particular those with new-onset or difficult to control
asthma. Asking if asthma symptoms differ during times
away from work such as weekends or holidays can be a
useful initial screening question.1 Those who answer
yes will require more detailed evaluation for possible
WRA. Due to the potential for the diagnosis to impact
employment, it is important to utilize objective testing
to confirm a diagnosis, as outlined in Table 4.
MANAGEMENT
The pharmacological treatment of WRA is the same as
that for non-WRA.1,37 A stepwise approach, using anti-
inflammatory and bronchodilator therapy, should be
used to achieve symptom control with subsequent dos-
age adjustment to achieve good symptomatic control at
the lowest effective dose, as per existing guidelines.37,49
For patients with difficult to control asthma symptoms,
there should be consideration of referral to a specialist
severe asthma clinic. Evaluation may include assess-
ment of eligibility for access to monoclonal antibody
therapy.
There is insufficient evidence that pharmacological
management of sensitiser-induced OA with inhaled
corticosteroids and long-acting β2-agonists is able to
prevent the long-term deterioration of asthma in sub-
jects who remain exposed to the agent causing OA.50
One study showed that early treatment with oral corti-
costeroids may improve outcomes for patients with IIA;
however, until confirmed this cannot be rec-
ommended.51 Every opportunity should be taken to
assist smoking cessation if relevant. The ATS has publi-
shed a position paper on WRA,16 and specific standards
of care were developed by the British Thoracic Society
and updated in 2012.52 These contain very similar rec-
ommendations, and can be applied worldwide. The
Australian Asthma Handbook (http://www.asthma
handbook.org.au) also has useful information.
Sensitiser-induced OA
Continued exposure will most likely lead to worsening
symptoms, airflow limitation and airway
hyperresponsiveness.53,54 Conversely, complete avoid-
ance will almost certainly result in improvement in
asthma control, although symptoms may remain in
two-third of cases.55
Optimal management of sensitiser-induced OA
involves accurate identification of the sensitiser and
early and complete avoidance of ongoing exposure.50,56
The latter may involve:
• Control of exposure at the workplace, including sub-
stitution with an alternative.
• Effective engineering controls.
• Other means to reduce air levels, such as extraction
ventilation or wetting the process for dusts.
• Redeployment to a job or work area with absence or
reduction of the exposure.5
• Use of protective clothing, masks or independent air
supplies, although low-level exposure may induce
symptoms in established sensitiser-induced asthma
despite protective equipment.50
• Communication with the employer (with patient
consent) regarding recommendations to eliminate or
reduce exposure.
• Seeking alternative employment.
Patients with confirmed or suspected sensitiser-
induced OA who continue to have potential exposure
to the sensitiser should be monitored closely by a
specialist. A recommendation has been made for
3 monthly reviews for 1 year and then 6 monthly
afterwards.52 Workers need to be counselled regard-
ing the risk of deteriorating asthma control and air-
flow obstruction posed by persistent occupational
exposure.
If a worker leaves a workplace due to OA, even if
based on medical recommendation, there is likely to
be a significant negative socio-economic impact for
that worker.57 The diagnosis should therefore be
objectively confirmed by a specialist with experi-
ence in investigating WRA, prior to making this
decision. Workers who have left the workplace may
have slow symptomatic and lung function improve-
ment and should be monitored for a minimum of
3 years.52
Irritant-induced OA
Workers should be able to continue their job unless
repetitive exposure to respiratory irritants is likely to
occur. Employers should ensure control measures are
in place to minimize the risk of exposure to respiratory
irritants for all workers as far as practicable. For those
with IIA, symptom control may be possible, whilst con-
tinuing their job, provided an effective reduction in
trigger exposure can be achieved in the workplace.18
Work-exacerbated asthma
The literature regarding the natural history and optimal
management of WEA is limited.1,16 Identification of
exacerbating triggers and reducing potential harmful
exposures can minimize the risk of ongoing problems.
Workers should be able to stay in the same job if con-
trol of exposure can be achieved, with close monitoring
of their asthma control.
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COMPENSATION AND IMPAIRMENT
ASSESSMENT
Most jurisdictions in Australia, as part of their
workers’ compensation system, have produced lists of
deemed diseases. These are conditions that are con-
sidered to be work related and the assumption is
made that an exposed worker with WRA is deemed to
have a work-related condition unless there is strong
evidence to the contrary.58 Therefore, it is important
that the diagnosis of WRA is accurately confirmed by
a specialist.
Persons suffering from WRA will commonly require
periods of time away from the workplace. Most will
consequently incur both social and financial costs,
including loss of income, medical fees and costs of
therapies. For these reasons, compensation will usually
be sought and is appropriate.
Early referral to the employer’s workers’ compensa-
tion insurer is recommended to allow timely assess-
ment of liability and institution of measures to address
the worker’s health. This may also expedite the process
of reducing exposure for other workers.
In cases with ongoing respiratory impairment, lump
sum compensation payments may be payable. An
assessment of permanent impairment should be del-
ayed until asthma symptoms have been stable for at
least 12 months. In all states of Australia, the assess-
ment of respiratory impairment is based on the Ameri-
can Medical Association Guides to the Evaluation of
Permanent Impairment. In general, the fourth (third
printing) and fifth editions are used and measured spi-
rometric indices are applied to the relevant tables pub-
lished in the guides. Requirements vary in the different
editions but all require:
• Measurements of pre- and post-bronchodilator spi-
rometry; predicted values as published in the guides.
• Determination that the lung function is stable (not
expected to vary by more than 3% in the future).
• A record of medication requirements59 including
inhaled glucocorticoids.
In Victoria, the Impairment Assessment in Workers
with OA is used as an extension of table 10 of the AMA
4th Edition guides and also takes into account clinical
symptomatology and exercise capacity.60
PREVENTION
All occurrences of WRA are potentially preventable.
Because a new diagnosis of OA is a sentinel event, the
managing clinician has an ethical responsibility to
communicate with the workplace and facilitate mea-
sures that protect co-workers. These may involve the
accurate identification of the causative exposure, a
review of workplace control measures, the introduction
or modification of a health surveillance programme to
screen other co-workers as well as optimizing case
management.61 Involvement of an occupational physi-
cian to address some of these issues may be warranted.
Ideally, a positive workplace culture will facilitate
workers to report safety concerns and potential early
symptoms of asthma.52
Elimination, substitution and enclosure
Elimination of the agent is strongly recommended as
the primary preventive method.62 An example has been
the substitution of powdered latex gloves by latex-free
gloves and powder-free, protein-poor natural rubber
latex (NRL) gloves minimizing occupational allergy and
asthma in health care.63
Exposure reduction
This is the next favoured approach if elimination is not
possible. Exposure levels are kept as low as feasible
through partial substitution, partial segregation and/or
optimization of ventilation by engineering controls
and/or automation of some work practices.64
Respiratory protective equipment as a preventive
measure is ranked lowest in the hierachy of con-
trols.61,62 If used, it must be appropriately selected for
the exposure (such as isocyanate-containing spray
paints),65 and adequate training of the workers must be
provided. Respiratory protection must be regularly fit
tested and well maintained. Powered or air supplied
respirators may be required to ensure a suitable degree
of protection is obtained.
Health surveillance
Although exposure reduction may lessen the progres-
sion of subclinical asthma and sensitisation, this strat-
egy also requires careful monitoring of workers for the
potential emergence of disease. Workplace surveillance
using questionnaires, followed by the investigation of
suggestive symptoms by a specialist clinician, is rec-
ommended.62 Serial spirometry, serological testing
and/or SPT as part of a more comprehensive medical
surveillance programme differ between industries
and/or individual workers and jobs within an industry.
Specific IgE (or SPT) surveillance is strongly rec-
ommended for ongoing potential exposure to HMW
agents such as animal care workers, bakers dust,
enzyme and latex exposures.66 It is also used for occa-
sional LMW allergens such as complex platinum salts.1
Although the evidence to support surveillance
programmes is considerable,61 optimal monitoring fre-
quency and efficacy of individual components have not
yet been established.
Pre-placement assessment
Testing of workers for specific sensitisation to HMW
allergens before employment is strongly recommended
for high-risk industries.62 Workers should be made
aware of the common sensitisers, existing control mea-
sures and typical symptoms of occupational rhinitis
and asthma that suggest a need for further evaluation
following commencement of work. For prospective
employees with pre-existing asthma and/or atopy,
results from screening investigations (such as spirome-
try and/or assessment of allergen-specific IgE) may be
used as a starting point for surveillance and health
education.66 While such applicants might consider
avoiding ‘at-risk’ employment, employer selection
based on these common predisposing conditions is not
useful as many workers will never develop WRA.14,66
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CONCLUSION
The development of asthma from an occupational
exposure is an important, preventable factor which has
substantial negative health and socio-economic impli-
cations for an individual. The worsening of asthma
control due to workplace conditions is also common
and requires careful management. Diagnosis of WRA
can be challenging and requires a thorough approach
with objective measures of respiratory function. The
influence of work on asthma should be considered as
part of routine asthma care, and if WRA is suspected,
early referral to a specialist for further evaluation and
management is usually required. Diagnosis of WRA
should also lead to evaluation of a workplace’s preven-
tion measures to minimize the risk to other exposed
workers.3
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